<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069415</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 21-001</org_study_id>
    <nct_id>NCT05069415</nct_id>
  </id_info>
  <brief_title>Monofocal IOL Visual Outcomes When Targeting Mini Monovision</brief_title>
  <official_title>Visual Performance and Patient Satisfaction With A New Monofocal Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolina Eyecare Physicians, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carolina Eyecare Physicians, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 3-month, prospective, up to 2 center, bilateral, randomized subject masked&#xD;
      clinical evaluation of a monofocal intraocular lens (IOL) when both eyes are targeted for&#xD;
      emmetropia and when the non-dominant eye is targeted for mini monovision (-0.75 D) in&#xD;
      patients with or without astigmatism undergoing routine cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular distance-corrected intermediate (66 cm) visual acuity at 3 months.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binocular low contrast distance visual acuity at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance-corrected near visual acuity at best distance at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectacle Independence Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Participants will answer a questionnaire to determine the need for glasses for near activities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Cataract</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Emmetropia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The target refraction for both eyes will be emmetropia (± 0.25 D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mini monovision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The target refraction for the dominant eye will be plano (± 0.25 D) and for the non-dominant eye between -0.75D ±0.15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eyhance IOL</intervention_name>
    <description>Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.</description>
    <arm_group_label>Emmetropia</arm_group_label>
    <arm_group_label>Mini monovision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eyhance IOL</intervention_name>
    <description>Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.</description>
    <arm_group_label>Emmetropia</arm_group_label>
    <arm_group_label>Mini monovision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is undergoing bilateral cataract extraction with intraocular lens&#xD;
             implantation.&#xD;
&#xD;
          -  Willing and able to provide written informed consent for participation in the study&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits and other study procedures.&#xD;
&#xD;
          -  Scheduled to undergo standard cataract surgery in both eyes within 6 - 30 days between&#xD;
             surgeries.&#xD;
&#xD;
          -  Subjects who require an IOL power in the range of +5.0 D to +34.0 D only.&#xD;
&#xD;
          -  Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both&#xD;
             eyes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative&#xD;
             diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment,&#xD;
             aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization,&#xD;
             medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve&#xD;
             atrophy, macular degeneration (with anticipated best postoperative visual acuity less&#xD;
             than 20/30), advanced glaucomatous damage, etc.&#xD;
&#xD;
          -  Uncontrolled diabetes.&#xD;
&#xD;
          -  Use of any systemic or topical drug known to interfere with visual performance.&#xD;
&#xD;
          -  Contact lens use during the active treatment portion of the trial.&#xD;
&#xD;
          -  Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.&#xD;
&#xD;
          -  Clinically significant corneal dystrophy.&#xD;
&#xD;
          -  Irregular astigmatism.&#xD;
&#xD;
          -  History of chronic intraocular inflammation.&#xD;
&#xD;
          -  History of retinal detachment.&#xD;
&#xD;
          -  Pseudoexfoliation syndrome or any other condition that has the potential to weaken the&#xD;
             zonules.&#xD;
&#xD;
          -  Previous intraocular surgery.&#xD;
&#xD;
          -  Previous refractive surgery.&#xD;
&#xD;
          -  Previous keratoplasty&#xD;
&#xD;
          -  Severe dry eye&#xD;
&#xD;
          -  Pupil abnormalities&#xD;
&#xD;
          -  Subject who may reasonably be expected to require a secondary surgical intervention at&#xD;
             any time during the study (other than YAG capsulotomy, i.e. LASIK)&#xD;
&#xD;
          -  Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).&#xD;
&#xD;
          -  Any clinically significant, serious or severe medical or psychiatric condition that&#xD;
             may increase the risk associated with study participation or may interfere with the&#xD;
             interpretation of study results.&#xD;
&#xD;
          -  Participation in (or current participation) any ophthalmic investigational drug or&#xD;
             ophthalmic device trial within the previous 30 days prior to the start date of this&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry D Solomon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolina Eyecare Physicians</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helga Sandoval</last_name>
    <phone>8438813937</phone>
    <email>hsandoval@cepmd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Sight</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Hagin</last_name>
    </contact>
    <contact_backup>
      <last_name>Gina Thomas</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Carolina Eyecare Physicians, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Sandoval</last_name>
      <phone>843-881-3937</phone>
      <email>hps@cepmd.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

